The circulating tumor DNA profiling of samples from r/r DLBCL patients who underwent CD19 CAR-T treatment determined the association of SOCS1, TNFAIP3, and XPO1 mutations with a poor prognosis after that therapy [117]. Here, CD19 is linked to diffuse large B-cell lymphoma.